

1.5
CME/CNE/CPE
CREDIT

Please join us for an accredited satellite
symposium at the 2024 Annual Scientific Meeting
of the Heart Failure Society of America

Where Are We With Cardiac Amyloidosis?



**Justin L. Grodin, MD, MPH,
FACC, FHFA**
PROGRAM CHAIR
Associate Professor of Medicine
University of Texas
Southwestern Medical Center
Dallas, TX



**Kevin Alexander, MD,
FACC, FHFA**
Assistant Professor of Medicine
Division of Cardiovascular Medicine
Stanford Medicine
Palo Alto, CA



**Amy Brownell, MSN,
FNP-C, FACC**
System Director of Heart Failure
Director of Cardiovascular Operations
Ascension Alexian Brothers
Medical Center
Elk Grove Village, IL

Friday, September 27, 2024

**Signia Atlanta Hotel
Triumph Ballroom H, 2nd floor
159 Northside Dr. NW, Atlanta, GA**

7:45pm – 8:00pm Registration/Dinner
8:00pm – 9:30pm CME Symposium

PROGRAM OVERVIEW

The goal of this activity is to improve the heart failure clinician's awareness and knowledge of Transthyretin Cardiac Amyloidosis (ATTR-CA) and the associated risks of HF. This increased knowledge will include a better understanding of the important role of new and emerging RNA interference (RNAi) therapies for the management of Hereditary Transthyretin Cardiac Amyloidosis (hATTR-CA); and the optimal use of TTR stabilizers and TTR silencers/knockdown agents along with heart failure and arrhythmia management.



Register Now!

[https://members.hfssa.org/events/event-registration/
?id=78a5d132-a74e-ef11-b4ad-6045bdb75d5f](https://members.hfssa.org/events/event-registration/?id=78a5d132-a74e-ef11-b4ad-6045bdb75d5f)

Registration for the 2024 HFSA Annual Scientific Meeting and an official name badge are required to attend this symposium.

This activity is supported by an educational grant from Alnylam Pharmaceuticals.

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee. The program topic, learning objectives, and faculty have been reviewed and approved by the ASM Program Review Committee for a satellite program at ASM 2024.

Accredited Provider



Where Are We With Cardiac Amyloidosis?

1.5
CME/CNE/CPE
CREDIT

AGENDA

- 8:00 pm** **Welcome/Introduction**
Justin Grodin, MD, MPH, FACC, FHFSa
- 8:05 pm** **ATTR Diagnosis: Current Best Practices and Emerging Horizons—Exploring Novel Techniques, Non-Invasive Approaches, and Biomarkers**
Justin Grodin, MD, MPH, FACC, FHFSa
- 8:30 pm** **Breaking Ground: The Latest Data and Game-Changing Therapies in ATTR**
Kevin Alexander, MD, FACC, FHFSa
- 8:55 pm** **ATTR in Focus: Engaging Case Vignettes and Real-World Insights**
Amy Brownell, MSN, FNP-C, FACC
- 9:05 pm** **Panel Discussion**
All
- 9:25 pm** **Closing Remarks/Adjourn**
Justin Grodin, MD, MPH, FACC, FHFSa

Times listed above are Eastern Daylight Time

TARGET AUDIENCE

The intended audience for this activity is physicians, nurses, nurse practitioners, physician assistants, and pharmacists.

LEARNING OBJECTIVES

The learning objectives for the proposed activity are based on the identified gaps and are designed to assess the participant's knowledge and competence. The objects are:

- Review the current practice on the diagnosis and initiation of treatment for patients with ATTR-CA
- Evaluate the current and emerging data on new therapies for the treatment of ATTR-CA
- Discuss the clinical trial data and role of RNAi therapies in the management of patients with ATTR-CA

ELIGIBILITY STATEMENT

Registration for the 2024 HFSA Annual Scientific Meeting and official name badge are required to attend this symposium. Live-stream viewing does not require meeting registration.



Register Now!

<https://members.hfsa.org/events/event-registration/?id=78a5d132-a74e-ef11-b4ad-6045bdb75d5f>



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: The Heart Failure Society of America designates this live activity for a maximum of **1.50 AMA PRA Category 1 Credits™**. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum **1.50** contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for **1.50** contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-24-016-L01-P.

Physician Associates:

The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.50** AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

